GlassScriptPhysician profile
Ernest James Kahn
NPI 1730475955
$1,233.80
in general payments reported to CMS, 2019-2025
21 companies · $875 in 2025
The $875 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $91.47 · 2024: $268 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $236.09 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $176.42 | 2024-2025 | |
| Lilly USA, LLC | $123.44 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $112.71 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $93.24 | 2024-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $79.53 | 2025 | Trelegy Ellipta |
| Cumberland Pharmaceuticals, INC. | $70.91 | 2020 | |
| Exact Sciences Corporation | $51.80 | 2024-2025 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $34.00 | 2024 | |
| Alk-Abello, INC | $30.87 | 2025 | Grastek, Odactra, Ragwitek |
| Bayer Healthcare Pharmaceuticals INC. | $30.75 | 2025 | |
| Hologic Sales and Service, LLC | $25.55 | 2024 | Aptima |
| Medtronic, INC. | $24.53 | 2025 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $22.65 | 2024 | Quviviq |
| Nevro Corp. | $20.62 | 2024 | Senza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20.56 | 2020 | |
| Abbott Laboratories | $17.65 | 2025 | Proclaim |
| Esperion Therapeutics, INC. | $16.79 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.61 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.16 | 2025 | Xifaxan |
| Tolmar, INC. | $13.92 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.